{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T12:22:38Z","timestamp":1769602958965,"version":"3.49.0"},"reference-count":8,"publisher":"American Society of Hematology","issue":"16","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2012,10,18]]},"DOI":"10.1182\/blood-2012-04-424192","type":"journal-article","created":{"date-parts":[[2012,10,18]],"date-time":"2012-10-18T16:46:17Z","timestamp":1350578777000},"page":"3382-3383","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":15,"title":["Characteristics and outcomes of patients with V299L BCR-ABL kinase domain mutation after therapy with tyrosine kinase inhibitors"],"prefix":"10.1182","volume":"120","author":[{"given":"Elias","family":"Jabbour","sequence":"first","affiliation":[{"name":"Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Van","family":"Morris","sequence":"additional","affiliation":[{"name":"Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hagop","family":"Kantarjian","sequence":"additional","affiliation":[{"name":"Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cameron C.","family":"Yin","sequence":"additional","affiliation":[{"name":"Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elizabeth","family":"Burton","sequence":"additional","affiliation":[{"name":"Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jorge","family":"Cortes","sequence":"additional","affiliation":[{"name":"Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"234","reference":[{"issue":"12","key":"2019111808321453800_B1","doi-asserted-by":"crossref","first-page":"4005","DOI":"10.1182\/blood-2007-03-080838","article-title":"Dynamics of BCR-ABL kinase domain mutations in chronic myeloid leukemia after sequential treatment with multiple tyrosine kinase inhibitors.","volume":"110","author":"Cortes","year":"2007","journal-title":"Blood"},{"issue":"5531","key":"2019111808321453800_B2","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1126\/science.1062538","article-title":"Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification.","volume":"293","author":"Gorre","year":"2001","journal-title":"Science"},{"issue":"10","key":"2019111808321453800_B3","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1038\/sj.leu.2404318","article-title":"Frequency and clinical significance of BCR-ABL mutations in patients with chronic myeloid leukemia treated with imatinib mesylate.","volume":"20","author":"Jabbour","year":"2006","journal-title":"Leukemia"},{"issue":"18","key":"2019111808321453800_B4","doi-asserted-by":"crossref","first-page":"4100","DOI":"10.1200\/JCO.2005.05.531","article-title":"ABL mutations in late chronic phase chronic myeloid leukemia patients with up-front cytogenetic resistance to imatinib are associated with a greater likelihood of progression to blast crisis and shorter survival: a study by the GIMEMA Working Party on Chronic Myeloid Leukemia.","volume":"23","author":"Soverini","year":"2005","journal-title":"J Clin Oncol"},{"issue":"3","key":"2019111808321453800_B5","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1200\/JCO.2008.19.8853","article-title":"Activity of bosutinib, dasatinib, and nilotinib against 18 imatinib-resistant BCR\/ABL mutants.","volume":"27","author":"Redaelli","year":"2009","journal-title":"J Clin Oncol"},{"key":"2019111808321453800_B6","doi-asserted-by":"crossref","article-title":"Activity of bosutinib by baseline and emergent mutation status in Philadelphia chromosome\u2013positive leukemia patients with resistance or intolerance to other tyrosine kinase inhibitors.","author":"Khoury","DOI":"10.1182\/blood.V118.21.110.110"},{"issue":"5","key":"2019111808321453800_B7","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1182\/blood-2010-12-326405","article-title":"BCR-ABL kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: recommendations from an expert panel on behalf of European LeukemiaNet.","volume":"118","author":"Soverini","year":"2011","journal-title":"Blood"},{"issue":"9","key":"2019111808321453800_B8","doi-asserted-by":"crossref","first-page":"2562","DOI":"10.1172\/JCI30890","article-title":"Sequential ABL kinase inhibitor therapy selects for compound drug-resistant BCR-ABL mutations with altered oncogenic potency.","volume":"117","author":"Shah","year":"2007","journal-title":"J Clin Invest"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/120\/16\/3382\/1498984\/zh804212003382.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/120\/16\/3382\/1498984\/zh804212003382.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,18]],"date-time":"2019-11-18T13:55:54Z","timestamp":1574085354000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/120\/16\/3382\/30772\/Characteristics-and-outcomes-of-patients-with"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,10,18]]},"references-count":8,"journal-issue":{"issue":"16","published-print":{"date-parts":[[2012,10,18]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2012-04-424192","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,10,18]]}}}